Insider Selling: Haemonetics Co. (NYSE:HAE) CEO Sells 1,248 Shares of Stock

Haemonetics Co. (NYSE:HAE) CEO Christopher Simon sold 1,248 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $109.37, for a total transaction of $136,493.76. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Christopher Simon also recently made the following trade(s):

  • On Friday, June 7th, Christopher Simon sold 2,834 shares of Haemonetics stock. The shares were sold at an average price of $103.38, for a total transaction of $292,978.92.
  • On Thursday, May 23rd, Christopher Simon sold 24,412 shares of Haemonetics stock. The shares were sold at an average price of $99.39, for a total transaction of $2,426,308.68.
  • On Monday, May 13th, Christopher Simon sold 57,587 shares of Haemonetics stock. The shares were sold at an average price of $94.51, for a total transaction of $5,442,547.37.

Shares of NYSE:HAE traded up $0.32 during trading hours on Friday, hitting $112.10. 33,842 shares of the company’s stock traded hands, compared to its average volume of 488,524. Haemonetics Co. has a 52 week low of $80.24 and a 52 week high of $117.56. The company has a current ratio of 2.44, a quick ratio of 1.62 and a debt-to-equity ratio of 0.48. The firm has a market cap of $5.64 billion, a price-to-earnings ratio of 46.91, a price-to-earnings-growth ratio of 2.78 and a beta of 0.67.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.06. Haemonetics had a net margin of 5.69% and a return on equity of 18.88%. The company had revenue of $249.30 million during the quarter, compared to analyst estimates of $250.62 million. During the same quarter last year, the firm posted $0.43 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, research analysts forecast that Haemonetics Co. will post 2.93 earnings per share for the current year.

Several large investors have recently bought and sold shares of HAE. Vanguard Group Inc boosted its position in shares of Haemonetics by 1.9% during the 3rd quarter. Vanguard Group Inc now owns 5,619,707 shares of the medical instruments supplier’s stock valued at $643,906,000 after purchasing an additional 107,357 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Haemonetics by 17.8% in the fourth quarter. Bank of Montreal Can now owns 2,052 shares of the medical instruments supplier’s stock worth $205,000 after buying an additional 310 shares during the period. Advisors Asset Management Inc. boosted its holdings in shares of Haemonetics by 67.1% in the fourth quarter. Advisors Asset Management Inc. now owns 10,571 shares of the medical instruments supplier’s stock worth $1,058,000 after buying an additional 4,245 shares during the period. Crossmark Global Holdings Inc. boosted its holdings in shares of Haemonetics by 20.1% in the fourth quarter. Crossmark Global Holdings Inc. now owns 5,549 shares of the medical instruments supplier’s stock worth $555,000 after buying an additional 930 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Haemonetics by 240.8% in the fourth quarter. SG Americas Securities LLC now owns 11,418 shares of the medical instruments supplier’s stock worth $1,142,000 after buying an additional 8,068 shares during the period. Institutional investors own 98.91% of the company’s stock.

Several equities analysts have commented on HAE shares. Zacks Investment Research cut shares of Haemonetics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. Barrington Research reissued an “outperform” rating and set a $116.00 target price (up previously from $112.00) on shares of Haemonetics in a research note on Wednesday, May 8th. TheStreet raised shares of Haemonetics from a “c+” rating to a “b-” rating in a research note on Tuesday, May 7th. Finally, Raymond James upgraded shares of Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price objective for the company in a research report on Tuesday, May 14th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $118.60.

COPYRIGHT VIOLATION NOTICE: This report was posted by Riverton Roll and is the sole property of of Riverton Roll. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://rivertonroll.com/news/2019/06/14/insider-selling-haemonetics-co-nysehae-ceo-sells-1248-shares-of-stock.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Article: What is the S&P 500 Index?

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.